PLX
$2.14-0.09 (-4.04%)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
Recent News
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
Protalix BioTherapeutics Inc (PLX) reports significant EU approval, financial gains, and R&D progress amidst increased expenses and market challenges.
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including a new European approval for its Fabry disease therapy and updated guidance for 2026. "2025 was a year of meaningful progress...
Protalix: Q4 Earnings Snapshot
HACKENSACK, N.J. (AP) — Protalix BioTherapeutics Inc. PLX) on Wednesday reported a loss of $5.5 million in its fourth quarter. On a per-share basis, the Hackensack, New Jersey-based company said it had a loss of 7 cents.
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen for pegunigalsidase alfa for adults with Fabry disease who are stable on enzyme replacement therapy (ERT), triggering a $25 million regulatory milestone payment from...
3 Promising Penny Stocks With Market Caps Up To $400M
The U.S. stock market kicked off February with a strong performance, as major indexes like the Dow Jones and S&P 500 posted significant gains. Amidst this backdrop of optimism, investors are exploring various opportunities across different market segments. While penny stocks might seem like a throwback to earlier trading days, they continue to offer intriguing possibilities for those interested in smaller or emerging companies with potential growth prospects.